The nitrogen-containing bisphosphonate zoledronic acid (ZOL), a potent inhibitor of farnesyl pyrophosphate synthase, blocks the mevalonate pathway, leading to intracellular accumulation of isopentenyl pyrophosphate/ triphosphoric acid I-adenosin-5 0 -yl ester 3-(3-methylbut-3-enyl) ester (IPP/ApppI) mevalonate metabolites. IPP/ ApppI accumulation in ZOL-treated cancer cells may be recognized by Vg9Vd2 T cells as tumor phosphoantigens in vitro. However, the significance of these findings in vivo remains largely unknown. In this study, we investigated the correlation between the anticancer activities of Vg9Vd2 T cells and the intracellular IPP/ApppI levels in ZOL-treated breast cancer cells in vitro and in vivo. We found marked differences in IPP/ApppI production among different human breast cancer cell lines post-ZOL treatment. Coculture with purified human Vg9Vd2 T cells led to IPP/ApppI-dependent near-complete killing of ZOL-treated breast cancer cells. In ZOLtreated mice bearing subcutaneous breast cancer xenografts, Vg9Vd2 T cells infiltrated and inhibited growth of tumors that produced high IPP/ApppI levels, but not those expressing low IPP/ApppI levels. Moreover, IPP/ ApppI not only accumulated in cancer cells but it was also secreted, promoting Vg9Vd2 T-cell chemotaxis to the tumor. Without Vg9Vd2 T-cell expansion, ZOL did not inhibit tumor growth. These findings suggest that cancers-producing high IPP/ApppI levels after ZOL treatment are most likely to benefit from Vg9Vd2 T-cellmediated immunotherapy. Cancer Res; 71(13); 4562-72. Ó2011 AACR.
Introduction
Nitrogen-containing bisphosphonates (NBP) are potent inhibitors of osteoclast-mediated bone resorption and can treat bone-loss disorders such as postmenopausal osteoporosis (1) , aromatase inhibitor-associated bone loss, and cancer treatment-induced bone loss (2) . In preclinical models, NBPs have direct and indirect antitumor properties (3) . NBPs inhibit farnesyl pyrophosphate synthase (FPPS), thus blocking the mevalonate pathway and preventing prenylation of G-proteins (e.g., Ras and Rho). In addition to effects on bone, this can inhibit tumor-cell invasion, proliferation, and adhesion (3) . Additional studies suggest that NBPs may also inhibit angiogenesis (3) . Importantly, there is now clinical evidence that adding the NBP zoledronic acid (ZOL) to endocrine therapy improves disease-free survival in estrogen-responsive early breast cancer (4, 5) and that adding ZOL to neoadjuvant chemotherapy reduces residual invasive breast cancer tumor size (6) . How ZOL mediates this activity is not understood.
Emerging data suggest that NBPs have immunomodulatory properties (7, 8) , which may have therapeutic applications. Some NBPs can induce expansion of human Vg9Vd2 T cells, the dominant subset of gd T cells (8) (9) (10) . NBP internalization by peripheral blood mononuclear cells (PBMC) inhibits FPPS, leading to intracellular accumulation of isopentenyl pyrophosphate (IPP) that, in turn, stimulates Vg9Vd2 T-cell proliferation in a Vg9Vd2 T-cell receptor (TCR)-dependent manner (11, 12) . The ATP analogue ApppI [triphosphoric acid I-adenosin-5 0 -yl ester 3-(3-methylbut-3-enyl) ester], which results from covalent binding of IPP and AMP (13) , can also act as a phosphoantigen, stimulating the expansion of Vg9Vd2 T cells from PBMCs (14) .
In preclinical models, Vg9Vd2 T cells activated by NBPs have potent antitumor effects in vitro (7, (15) (16) (17) (18) , and Vg9Vd2 T cells expanded in vitro maintain antitumor activity upon adoptive transfer into immunodeficient mice inoculated with melanoma or pancreatic adenocarcinoma cells (15) . ZOL also enhances Vg9Vd2 T-cell cytotoxicity in experimental models of chronic myelogenous leukemia and lung, colon, or bladder cancer (18) (19) (20) (21) . In addition, clinical evidence suggests anticancer effects of the Vg9Vd2 T cells in patients with lymphoid malignancies treated with the NBP pamidronate þ interleukin-2 (IL-2; refs. 7, 22) , and in patients with castration-resistant prostate cancer or advanced metastatic breast cancer treated with ZOL þ IL-2 (23, 24) . A single dose of ZOL has also been shown to durably activate gd T cells in patients with breast cancer (25) .
Cancer cells may be especially vulnerable to Vg9Vd2 T cells (10, 11) , even though the antitumor activity of Vg9Vd2 T cells against different tumor cells treated with NBPs varies (26) . Interestingly, IPP/ApppI production after NBP treatment in different cell lines also varies (27) , and these mevalonate metabolites could be recognized by Vg9Vd2 T cells as tumor phosphoantigens (10, 14) , suggesting that the anticancer potency of Vg9Vd2 T cells might depend on intracellular IPP/ApppI levels in NBP-treated tumors. However, there is no in vivo evidence that a NBP can induce IPP/ApppI accumulation in tumors. In addition, the reasons why IPP/ApppIproducing tumors may become vulnerable to Vg9Vd2 T cells in vivo remain unexplored. In the present study, the correlation between the potency of Vg9Vd2 T cells to kill cancer cells and intracellular IPP/ApppI levels in ZOL-treated breast cancer cells was investigated in vitro and in vivo.
Materials and Methods

Drugs, cell culture, and animals
Unlabeled and carbon 14 ( 14 C)-labeled ZOL was provided by Novartis Pharma AG. Recombinant IL-2 was provided by Novartis Pharmaceuticals Ltd. Sterile stock bisphosphonate solutions were prepared in PBS (pH 7.4; Invitrogen).
Five-week-old female nonobese diabetic severe combined immunodeficient (NOD/SCID) mice were purchased from Charles River Laboratories. All procedures involving animals, including their housing and care, the method by which they were killed, and experimental protocols, were conducted in accordance with a code of practice established by the local ethical committee (CREEA: Comit e R egional d'Etique pour l'Exp erimentation Animale).
Blood was donated by healthy volunteers or obtained from the Blood Transfusion Center (Etablissement Français du Sang). Human PBMCs were isolated after Ficoll-Paque (Amersham Biosciences) density gradient centrifugation. The Vg9Vd2 T cells were expanded by exposing PBMCs to 10mmol/L ZOL plus 100-U IL-2 for 14 days. Populations of Vg9Vd2 T cells were purified by positive selection of TCR gd cells using immunomagnetic cell sorting (AutoMACS Ò Pro Separator, Miltenyi Biotec).
Human breast cancer cell lines (T47D, MCF-7, BT-474, ZR-75-1, MDA-MB-231, MDA-MB-435, MDA-MB-435s) were obtained from the American Type Culture Collection (ATCC)-LGC Promochem and used within 6 months. All cell lines were authenticated using short tandem repeat analysis. The human estrogen-receptor (ER)-negative B02 breast cancer cell line, a subpopulation of MDA-MB-231, was prepared as previously described (28) . PBMCs and ZR-75-1 breast cancer cells were cultured in RPMI-1640 medium (ATCC) supplemented with 10% fetal bovine serum (Invitrogen) and penicillin/streptomycin (Invitrogen). BT-474 breast cancer cells were cultured in Hybri-Care medium (ATCC) supplemented with 1.5 g/L NaHCO3, 10% fetal bovine serum and penicillin/ streptomycin (Invitrogen). Other breast cancer cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) medium (Invitrogen) supplemented with 10% fetal bovine serum and penicillin/streptomycin.
In vitro and in vivo Vg9Vd2 T-cell expansion and IFN-g measurement
PBMCs were seeded in 24-well plates (1 Â 10 6 cells/well) and then treated with vehicle (PBS) or ZOL (1, 10, or 100 mmol/L) AE IL-2 100 U/mL for 7, 14, 21, and 28 days. IL-2 was renewed at day 4 and then every 3 days. In vivo expansion of Vg9Vd2 T cells was carried out in NOD/SCID mice. PBMCs (3.5 Â 10 7 ) were inoculated intraperitoneally (i.p.), and mice were treated with vehicle or ZOL (3, 10, or 30 mg/kg), i.p., and 10,000-U IL-2. Mice then received IL-2 plus vehicle or ZOL every 2 days for 14 days. On day 14, mice were sacrificed and peritoneal cells collected for analysis of Vg9Vd2 T cells. Percentages of Vg9Vd2 T cells in PBMCs and peritoneal cells were determined by flow cytometry (FACScan, Becton Dickinson) after immunostaining with anti-CD3-PE (BD Pharmingen) and anti-Vd2-TCR-FITC antibodies (Beckman Coulter). Human IFN-g in the serum from mice was measured using a commercial ELISA kit (Biosource).
IPP/ApppI analysis
ZOL-induced IPP/ApppI production was measured in PBMCs and breast cancer cells in vitro and in s.c. tumors in vivo. PBMCs (3 Â 10 6 ) were exposed to PBS or ZOL (1, 10, or, 100 mmol/L) plus 100 U/mL IL-2, then cultured on 6-well plates for 1, 2, 4, 7, 11, and 14 days. T47D, MCF-7, and B02 breast cancer cells were seeded in 6-well plates at 1 Â 10 6 cells/well overnight. Cells were pulse-treated with 25-mmol/L ZOL for 1 hour, then incubated without drug for 0 to 42 hours. Cells were then scraped and washed in PBS and extracted using ice-cold acetonitrile (300 mL) and water (200 mL) containing 0.25-mmol/L NaF and Na 3 VO 4 to prevent degradation of IPP and ApppI. Tumor xenografts were collected from mice after sacrifice and snap-frozen in liquid nitrogen, pulverized, and extracted using ice-cold acetonitrile. IPP and ApppI in cell extracts were quantified by high-performance liquid chromatography negative ion electrospray ionization mass spectrometry (HPLC-ESI-MS; ref. 13) .
Cellular uptake assay for ZOL T47D, MCF-7, and B02 cells were seeded overnight to 10-cm Petri dishes at 4 Â 10 6 cells/dish and then treated with 14 C-labeled ZOL for 1 hour. Cells were then rinsed with PBS, scraped, and extracted with acetonitrile and water. Extracts were separated by centrifugation (14,000Âg, 2 minutes). Precipitates were analyzed for total protein content by a modified Bradford procedure. The soluble acetonitrile/water extracts were evaporated and redissolved in 120-mL Milli-Q water, then mixed with OptiPhase HiSafe3 scintillation cocktail (PerkinElmer Wallac) and evaluated by liquid scintillation (TriLux Microbeta, PerkinElmer Wallac).
3-Hydroxy-3-methylglutaryl-coenzyme A reductase analysis by Western blotting
T47D, MCF-7, and B02 cells were treated with vehicle (0.5% DMSO) or 0.3-mmol/L lovastatin for 24 hours and then lysed in 100-mL cell lysis buffer [1% (vol/vol) Nonidet P-40 in 0.05M Tris-HCL containing 0.15-M NaCl, 1-mM EDTA, 0.05-M NaF and a cocktail of protease inhibitors (1-mM PMSF, 1-mg/ml aprotinin, 1-mg/mL leupeptin and 1-mmol/L NA 3 VO 4 )]. For each sample, 50-mg protein was used for SDS-polyacrylamide gel electrophoresis, and transferred onto a polyvinylidene difluoride (PVDF) membrane (Invitrogen), which was then washed with PBS/0.1% Tween and incubated overnight at 4 C with a rabbit polyclonal anti-3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase Ab (1/500 in 5% nonfat milk; Upstate). After washing, membranes were incubated with HRP-conjugated antirabbit Ab (GE Healthcare) and developed using Western Lightning Chemiluminescence (Per-kinElmer LAS Inc.). As a control, washed membranes were incubated with horseradish peroxidase (HRP)-conjugated antimouse Ab (GE Healthcare) and then developed as before. Densitometric analysis of blots was carried out using Quantity One software (Bio-Rad Laboratories).
Cytotoxicity assay
T47D, MCF-7, and B02 breast cancer cells had different growth rates in culture. For cytotoxicity assessments, it was therefore necessary to adjust the cell number at the beginning of the experiment in order to have cell monolayers at a similar confluence at the time of the coculture with Vg9Vd2 T cells. In this respect, T47D (2 Â 10 4 cells/well), MCF-7 (2 Â 10 4 cells/ well), and B02 (7 Â 10 3 cells/well) breast cancer cells were incubated overnight, then treated for 1 hour with vehicle (PBS) or ZOL (1-25 mmol/L). Cell monolayers were then washed; 18 hours later, breast cancer cells were cocultured with or without purified Vg9Vd2 T cells (cancer cell:Vg9Vd2 T-cell ratio was 1:12.5 or 1:25) for 4 hours or 24 hours. Viability was assessed by MTT assay.
Experimental tumorigenesis
Five-week-old female NOD/SCID mice were injected s.c. in the flank with 5 Â 10 6 B02 or T47D cells in 100-mL PBS. For the ER-positive T47D cells, host mice were implanted with s.c. 60day-release pellets containing 1.7-mg 17b-estradiol (Innovative Research of America) 4 days before tumor-cell inoculation. Four weeks later, when B02 and T47D tumors had reached a volume of 50 mL, mice were randomly assigned to 4 treatment groups (n ¼ 6-7 mice/group): placebo (PBS); ZOL at 30 mg/kg body weight; human PBMCs (3.5 Â 10 7 ) injected i.p. plus 10,000-U IL-2 administered alone or with 30mg/kg ZOL. In the relevant groups, IL-2 and ZOL in 0.5-mL PBS were administered i.p. every 2 days for 14 days. Tumor size was calculated by external measurement of the width (m 1 ) and length (m 2 ) of s.c. tumor xenografts using a Vernier caliper. Tumor volume (TV) was calculated using the equation
At the end of the protocols, mice were sacrificed and tumors collected for immunohistochemistry and real-time PCR.
Immunohistochemistry
Tumors were embedded in Tissue-Tek (Sakura), snap-frozen in liquid nitrogen-cooled isopentane, and stored at-70 C. Frozen 7-mm sections were cut in a cryostat, air-dried, and fixed in cold acetone. After washing in PBS, tissue sections were preincubated with 1% goat serum. For detection of Vg9Vd2 T cells, tumor sections were incubated with a fluorescein isothiocyanate (FITC)-conjugated antihuman TCR d2 monoclonal Ab, diluted 1:20 in PBS/1% BSA/0.3% Triton X-100. Cell nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI; Roche). Tissue sections were rewashed and visualized by fluorescence microscopy (Axioskop 40; Zeiss). To measure tumor-cell proliferation, tumor sections were incubated with a rabbit polyclonal anti-Ki-67 Ab (Abcam). Experiments were carried out as previously described (28) . The mitotic index was expressed as percentage of Ki-67-positive nuclei.
Real-time PCR
Total RNA was extracted from T47D and B02 tumors and infiltrating Vg9Vd2 T cells. Tumors were homogenized with a Polytron device (Kinematica). RNA was extracted using the nucleospin RNA II kit (Macherey-Nagel) followed by DNase digestion (Macherey-Nagel). Samples of total RNA (1.5-5 mg) were reverse-transcribed using Superscript II (Invitrogen). real-time PCR was carried out (IQ SYBR Green, Bio-Rad) with primers specific for the human housekeeping gene L32 (100 bp), a ribosomal protein used as an internal standard: 5 0 caaggagctggaagtgctgt; 3 0 cagctctttccacgatggc, and human TCR Vd2 (162 bp): 5 0 caaaccatccgtttttgtc; 3 0 cttgacag cattgtacttcc. We confirmed the linear range of amplification for all primers and products. Real-time reverse transcriptase (RT)-PCR was carried out using the Mastercycler EP system (SYBR Green; Realplex2). Amplimers were quantified in triplicate samples in the pool of 3 independent tumors for each gene and normalized to corresponding L32 values.
Transwell migration assay
T47D, MCF-7, and B02 breast cancer cells were seeded overnight to 6-well plates at 10 6 cells/well. The cells were then treated for 1 hour with PBS or 25-mmol/L ZOL AE 10-mmol/L lovastatin. Cells were then washed twice with PBS and cultured for 18 hours in DMEM þ 0.25% BSA. The conditioned medium from treated or untreated breast cancer cell lines was collected and centrifuged for use in migration assays. Migration assays were carried out in 24-well Transwell plates (Corning Costar) with 5-mm pore polycarbonate membrane. Before migration assays, Vg9Vd2 T cells were enriched by PBMC culture with 10-mmol/L ZOL plus 100 U IL-2 for 10 to 14 days. Purified populations of Vg9Vd2 T cells obtained by positive selection of TCR gd were resuspended at 3 Â 10 6 cells/ 100 mL in assay buffer. A cell suspension (100 mL) was placed in the upper chamber of the Transwell inserts, and 600 mL of conditioned medium from breast cancer cell lines, plus 1 mmol/L ApppI or 0.5 mmol/L IPP, were placed in the lower chamber. After incubation for 4 or 24 hours at 37 C, cells from the lower chamber were counted. Basal cell-culture medium was used as a control to measure random migration of Vg9Vd2 T cells in the absence of chemoattractant. The control was set to 100%, and the results obtained in the presence of a chemoattractant were expressed as a percentage of the control.
Human cytokines released from vehicle-and ZOL-treated T47D and B02 cells were detected using RayBio Human Cytokine Ab Array C series 1000, designed to detect 120 cytokines (Ray Biotech). The array membranes were incubated overnight with conditioned medium (1.2 mL/1.2 mg protein) from cultured T47D and B02 cells treated or untreated with ZOL. Detection of immunoreactive spots was carried out using an enhanced chemiluminescence detection system.
Human chemokines IL-8, IL-6, and monocyte chemoattractant protein-1 (MCP-1; eBioscience) released from vehicleand ZOL-treated T47D, MCF-7, and B02 cells were measured by ELISA.
Statistical analysis
All data were analyzed using StatView software (version 5.0; SAS Institute Inc.). Pairwise comparisons were carried out by conducting a nonparametric Mann-Whitney U test. P values < 0.05 were considered statistically significant. All statistical tests were two-sided.
Results and Discussion
ZOL induces human Vg9Vd2 T-cell expansion in vitro and in vivo ZOL stimulated, in a time-and dose-dependent manner, expansion of Vg9Vd2 T cells from human PBMCs, peaking at day 14 with a 10-mmol/L ZOL concentration (Fig. 1A) . These results are in accordance with previous reports showing that NBPs stimulate proliferation of Vg9Vd2 T cells in vitro (29) . In addition, mass spectrometry revealed rapid IPP accumulation in PBMCs after 1-2 days of ZOL treatment (Fig. 1B) , whereas ApppI was detected after 2-4 days (Fig. 1C) . No reactivity of murine gd T cells to phosphoantigens such as IPP or ApppI has yet been shown, and human gd T cells do not recognize cells from animals other than humans (11, 30) . Thus, murine PBMCs treated with an amino-bisphosphonate do not activate murine or human gd T cells. The effect of ZOL on Vg9Vd2 T-cell expansion was therefore studied in vivo after i.p. injection of human PBMCs into NOD/SCID mice and ZOL þ IL-2 treatment. ZOL stimulated expansion of Vg9Vd2 T cells such that they comprised up to 16% of T lymphocytes, versus 2.7% for IL-2 alone ( Fig. 1D and E) . This is explained by the fact that ZOL is internalized by antigen-presenting cells from human PBMCs where it induces the intracellular accumulation of IPP/ApppI and subsequent activation of Vg9Vd2 T-cell expansion (12) , making our animal model most suitable for studying the role of ZOL in cancer immunotherapy in vivo. Moreover, although ZOL was administered more frequently in our model than the current clinical dosing regimen in humans, the dose given (30 mg/kg) was lower than the dosing in humans (100 mg/kg), supporting the clinical relevance of our findings.
A D E
ZOL induces IPP/ApppI production in human breast cancer cells in vitro
Prior studies showed the intracellular accumulation of IPP and ApppI in NBP-treated cancer cell lines in vitro (10, 27) . In our study, ZOL-induced IPP/ApppI production was quantified in a series of human breast cancer cell lines having a luminal [ER-positive and/or progesterone receptor (PR)-positive and Ki-67-positive] or basal (ER-, PR-, and HER2-negative) molecular subtype. Mass spectrometry analysis showed that IPP/ ApppI levels varied substantially among breast cancer cell lines after ZOL treatment ( Fig. 2A) . Specifically, 3 of the 4 luminal breast cancer cell lines studied (T47D, MCF-7, BT-474, ZR-75-1) produced IPP/ApppI, whereas none (0/4) of the basal breast cancer cell lines tested (MDA-MB-231, B02, MDA-MB-435, and MDA-MB-435s) produced these phosphoantigens. In addition, we found that IPP/ApppI accumulation in ZOL-treated T47D cells was time-dependent, with IPP reaching a maximum concentration at 12 hours (1,052 pmol/ mg protein) and ApppI peaking at 24 hours (1,302 pmol/mg protein) (Fig. 2B) . These results were in line with our previous findings showing that the basal MCF-10A and MDA-MB-436 breast cell lines produced low levels of IPP/ApppI after ZOL treatment (27) . The higher IPP/ApppI production in luminal versus basal breast cancer cell lines is, to our knowledge, a novel observation.
Three breast cancer cell lines having a high (T47D), medium (MCF-7), or low (B02) production of phosphoantigens were then selected for subsequent experiments. Fluid-phase endocytosis is the major route by which NBPs are internalized in macrophages and osteoclasts (31) . Variations in endocytosis between the cancer cell lines might explain differences in IPP/ ApppI production induced by ZOL. Uptake of 14 C-labeled ZOL was therefore measured in T47D, MCF-7, and B02 cells. Uptake was similar in T47D and MCF-7 cells, but 3-fold lower in B02 cells (Fig. 2C ). In addition, we found a strong correlation between HMG-CoA reductase expression, a mevalonate pathway enzyme upstream of FPP synthase, and ZOL-induced IPP/ ApppI accumulation (Fig. 2D ). As shown by Western blotting, lovastatin (an HMG-CoA reductase inhibitor) substantially increased HMG-CoA reductase protein levels in ER-positive T47D and MCF-7 cells (Fig. 2D) . By contrast, HMG-CoA reductase was undetectable, and only a faint protein band was observed in lovastatin-treated ER-negative B02 cells (Fig. 2D) . These results agree with data reported by Borgquist and colleagues (32) who showed that high HMG-CoA reductase expression correlated positively with ER expression in tumor tissue from patients with breast cancer. Altogether, these results show that IPP/ApppI production in breast cancer cells depends on cellular uptake of NBP and on the activity of the mevalonate pathway. Moreover, we suggest that luminal neoplastic mammary epithelial cells might be more sensitive to bisphosphonate therapy than basal neoplastic mammary epithelial cells.
Vg9Vd2 T-cell cytotoxicity correlates with ZOL-induced IPP/ApppI accumulation in breast cancer cells in vitro and in vivo
The antitumor potency of human Vg9Vd2 T cells against ZOL-treated breast cancer cell lines was first examined in vitro (Figs. 3A-3F ). Incubation for 1h with ZOL (1-25 mmol/L) did not affect survival of T47D, MCF-7, and B02 cells (Figs. 3A, 3C , and 3E, respectively), whereas these bisphosphonate concentrations did induce intracellular IPP/ApppI accumulation in T47D and MCF-7 cells ( Figs. 2A-B ). Coculture of ZOL-treated T47D cells with purified Vg9Vd2 T cells led to dose-dependent cancer-cell death, which was statistically significant with ZOL at concentrations as low as 1 mmol/L for 1 hour (Fig. 3B ). In addition, Vg9Vd2 T cells caused ZOL-treated MCF-7 cell death; concentrations of ZOL !10 mmol/L were required to prime MCF-7 cells for Vg9Vd2 T-cell-mediated cytotoxicity (Fig. 3D) . In sharp contrast, Vg9Vd2 T cells were not cytotoxic against ZOL-treated B02 cells (Fig. 3F) . Although human cancer cell lines exhibit susceptibility to Vg9Vd2 T-cell-mediated cytotoxicity upon NBP treatment, the in vitro antitumor activity of Vg9Vd2 T cells against tumor cells treated with NBPs varies greatly (10, 11, 15) . For example, Vg9Vd2 T cells fail to efficiently kill a variety of human renal (ACHN, Caki-2, A-704) and gastric (MKN45, MKN74) cancer cell lines after NBP pretreatment (11) . Here, our results strongly suggest that ZOL-induced IPP/ApppI accumulation in breast cancer cells was responsible for Vg9Vd2 T-cellmediated cytotoxicity. In this respect, cotreatment of T47D cells with ZOL þ lovastatin almost completely eliminated IPP/ApppI phosphoantigen production by these cells and substantially reduced Vg9Vd2 T-cell cytotoxicity (Supplementary Fig. S1 ). It is therefore most conceivable that the lack of cytotoxicity of Vg9Vd2 T cells against some cancer cell lines is attributable to a low intracellular accumulation of phosphoantigens upon NBP treatment of cancer cells, likely because of the low activity level of the mevalonate pathway. We next conducted in vivo experiments to examine the contribution of IPP/ApppI accumulation in breast tumors to Vg9Vd2 T-cell cytotoxicity. Earlier experimental in vivo studies used human Vg9Vd2 T cells expanded in vitro and then purified before inoculation (15, 18, 19, 20) . Here, we showed that ZOL þ IL-2 treatment induced Vg9Vd2 T-cell expansion from human PBMCs injected i.p. into NOD/SCID mice (Fig. 1E) . In the clinic, it has been recently shown that the treatment of patients with advanced breast cancer with ZOL and low-dose IL-2 triggers Vg9Vd2 T-cell amplification in vivo (24) . We therefore chose to use this therapeutic strategy to treat tumor-bearing animals. NOD/SCID mice bearing sub-cutaneous breast cancer xenografts were inoculated with human PBMCs, with expansion of Vg9Vd2 T cells in vivo (Fig. 4) . Treatment with ZOL alone or PBMCþIL-2 did not inhibit s.c. tumor growth ( Fig. 4A and B) . In contrast, PBMC þ IL-2 þ ZOL completely blocked growth progression of T47D tumors, compared with that observed in placebo-treated animals (P < 0.01; Fig. 4A ). In addition, in situ immunodetection of the proliferation marker Ki-67 nuclear antigen in T47D tumors from mice treated with PBMC þ IL-2 þ ZOL showed drastic reduction in proliferative index versus tumors from placebo-treated mice (Fig. 4C ). However, this treatment did not inhibit growth or proliferative index of B02 s.c. tumors Tumor sections were stained with TCR Vd2 (green) and DAPI (nuclei, blue). Results are mean AESD of 6 to 7 mice per group. ns, not significant; *, P < 0.05; **, P < 0.01 compared with placebo.
( Fig. 4B and D) . Of note, Vg9Vd2 T-cell infiltrates were detected in T47D but not B02 tumors from mice treated with PBMC þ IL-2 þ ZOL ( Fig. 4E-G) , as judged by both RT-PCR and immunohistochemistry. Moreover, serum levels of human IFN-g were high in T47D-tumor-bearing mice treated with PBMCs þ IL-2 þ ZOL (942 AE 240 pg/mL, n ¼ 5) and moderate in animals treated with PBMCs þ IL-2 (563 AE 370 pg/mL, n ¼ 5), whereas the cytokine was not detected in animals treated with placebo or ZOL alone, showing that Vg9Vd2 T cells were activated in vivo.
Because Vg9Vd2 T cells infiltrated s.c. T47D tumor xenografts in mice treated with PBMC þ IL-2 þ ZOL ( Fig. 4E and  4G ), IPP/ApppI was measured in tumor extracts by mass spectrometry. As expected, IPP and ApppI were barely detectable in T47D tumors from placebo-treated mice (Fig. 5A) , whereas IPP levels were substantial 24 hours after the last ZOL dose in mice treated with PBMC þ IL-2þ ZOL (3.7 pmol; 82 nmol/L) ( Fig. 5B ). By contrast, ApppI remained undetectable at 24 hours. Conversely, lower IPP levels were detected at 48 hours after the last ZOL dose in PBMC þ IL-2 þ ZOLtreated mice (0.7 pmol; 16 nmol/L), whereas ApppI levels were measured (0.11 pmol; 2.5 nmol/L; Fig. 5C ). Of note, IPP and ApppI were also detected in T47D tumor extracts from mice treated with ZOL alone. In contrast, ZOL-induced IPP/ApppI was not detected in B02 tumor xenografts (not shown).
These data, to the best of our knowledge, show for the first time that s.c. tumors can produce IPP/ApppI after ZOL administration, showing the uptake of the NBP into tumor cells in vivo. If IPP/ApppI had been produced by tumorinfiltrating cells (e.g., macrophages), we would have expected IPP/ApppI also to be produced in B02 tumors, contrary to what we observed in vivo. It is interesting that Guenther and colleagues (33) recently reported, based on their use of a mouse xenograft model for plasmacytoma, that the treatment of animals with ZOL leads to accumulation of unprenylated Rap1A (a surrogate marker of the inhibitory effect of NBP on the mevalonate pathway) in plasma cell tumors ex vivo. These findings (33) , along with our present data, provide evidence for a direct uptake of ZOL in tumor cells in vivo. However, in our breast cancer model, ZOL treatment without PBMC þ IL-2 (i.e., without Vg9Vd2 T-cell expansion) did not inhibit tumor growth, showing the important role of human Vg9Vd2 T cells in the antitumor activity of NBPs.
IPP and ApppI released by breast cancer cells are chemotactic factors for Vg9Vd2 T cells In our model, ZOL was able to induce recruitment of Vg9Vd2 T cells to T47D tumors. We therefore investigated the ability of breast cancer cells treated in vitro with ZOL to promote Vg9Vd2 T-cell migration. Using conditioned medium from untreated breast cancer cell lines (T47D, MCF-7, B02) in Transwell migration assays, we observed significantly enhanced migration of Vg9Vd2 T cells after 4 hours (not shown) and 24 hours ( Fig. 6A ; P < 0.05 and P < 0.01) versus assay buffer. Migration of Vg9Vd2 T cells was much higher with conditioned medium from ZOL-treated T47D and MCF-7 breast cancer cells ( Fig. 6B and C) . In addition, conditioned medium from T47D cells treated with ZOL þ lovastatin resulted in less migration of Vg9Vd2 T cells (Fig. 6C ). To clarify whether IPP/ApppI acted as migration factors for Vg9Vd2 T cells, we used mass spectrometry to measure IPP levels in conditioned medium from ZOL-treated breast cancer cell lines (T47D, MCF-7, B02). We found substantial IPP levels in conditioned medium from ZOL-treated T47D and MCF-7 cells, but not B02 cells (data not shown). Moreover, 0.5-mmol/L IPP or 1-mmol/L ApppI significantly stimulated gd T-cell migration (Fig. 6C) . Because ApppI can be converted into IPP on hydrolysis by nucleotide pyrophosphatases (14) , it also may be processed into IPP for subsequent recognition by the Vg9Vd2 TCR. The cytokines IL-6, IL-8, and MCP-1 are also gd T-cell chemoattractants (30) . However, we found no differences in these or any other cytokines in a human cytokine antibody array of conditioned medium from untreated or ZOL-treated T47D, MCF-7, and B02 cells (Fig. 6D ). Although B02 cells produced a greater range of cytokines than T47D cells, cytokine profiles were similar for ZOL-treated or Figure 6 . IPP and ApppI induce chemotactic migration of Vg9Vd2 T cells. Purified Vg9Vd2 T cells isolated from ZOL-stimulated PBMCs by positive selection of TCR-gd cells were tested in a Transwell assay for their capacity to migrate (A) toward conditioned medium (CM) from T47D, MCF-7, and B02 cell lines compared with assay medium alone; (B) toward CM from ZOL-treated T47D, MCF-7, and B02 cells versus CM from untreated cells; or (C) toward CM from ZOL-treated T47D cells AE lovastatin and 0.5-mmol/L IPP or 1-mmol/L ApppI added in the medium, or compared with assay medium alone. Data represent mean percentage migration from 2 independent experiments AE SD. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 using pairwise comparisons with the assay medium or CM from untreated cells. ns, not significant. D, detection of cytokines produced in the supernatant by cultured, untreated (control; CTR), and ZOL-treated T47D and B02 cells using 2 human cytokine antibody array membranes (1 and 2) designed to detect altogether 120 human cytokines. E, IL-6, IL-8, and MCP-1 secretion in CM of T47D, MCF-7, and B02 cells, using ELISA.
untreated cells (Fig. 6D ). By ELISA, untreated B02 cells (control) produced more IL-8 and MCP-1 compared with T47D or MCF-7 control cells (Fig. 6E) ; IL-6 was detected only in B02 cells.
In conclusion, our study shows for the first time that ZOL induces the production of IPP/ApppI phosphoantigens by breast tumors in vivo, which, in turn, promote chemotaxis and cytotoxicity of Vg9Vd2 T cells. These results provide some support for an adjuvant role of NBPs in breast cancer. There is now clinical evidence that adding ZOL to endocrine therapy improves disease-free survival in ER-responsive early breast cancer (4, 5) . ZOL has also been shown to durably activate gd T cells in patients with breast cancer (25) . The immunomodulating role of NBPs on human gd T cells might explain, at least in part, the anticancer effects of ZOL observed in these adjuvant clinical trials. Overall, our findings suggest that cancers producing high IPP/ApppI levels after ZOL treatment are most likely to benefit from Vg9Vd2 T-cell-mediated immunotherapy.
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